Adrian Miranda1, Arturo Taca2,3. 1. a Department of Pediatrics, Division of Gastroenterology and Hepatology , Medical College of Wisconsin , Milwaukee , WI , USA. 2. b St. Louis University School of Medicine , St. Louis , MO , USA. 3. c INSynergy Treatment Program , St. Louis , MO , USA.
Abstract
BACKGROUND: Finding an effective, non-pharmacological approach to treat opioid withdrawal could remove some of the barriers associated with pharmacotherapy. The BRIDGE® is a noninvasive, percutaneous electrical nerve field stimulator developed to target pain. OBJECTIVES: This pilot study aimed to determine (1) the effects of the BRIDGE on withdrawal scores during the induction phase of opioid withdrawal therapy, (2) the percentage of subjects who successfully transitioned to medication assisted therapy (MAT). METHODS: Adult patients treated with the BRIDGE during medically supervised withdrawal were included in this open label, uncontrolled, and retrospective study. The clinical opioid withdrawal scale (COWS) scores were prospectively recorded at different intervals (20, 30, and 60 min) and analyzed retrospectively. A subset of patients had scores recorded 5-days post-BRIDGE. Those who returned to the clinic and received their first dose of maintenance medication were considered to be successfully transitioned. RESULTS: In this cohort (n=73), 65% were male. The mean COWS score prior to BRIDGE placement was 20.1 (±6.1). Twenty minutes after BRIDGE placement, the mean score was reduced to 7.5 (±5.9) (62.7% reduction, p<0.001). The scores further decreased after 30 minutes 4.0 (±4.4) and 60 minutes 3.1 (±3.4) (84.6% reduction, p<0.001). No rescue medications were administered during this period. The mean withdrawal score on day 5 was 0.6 (97.1% reduction, p<0.001) (n=33). Overall, 64/73 patients (88.8%) successfully transitioned to MAT. CONCLUSIONS: Neurostimulation with the BRIDGE is associated with a reduction in opioid withdrawal scores. This effect persisted during the induction period and allowed for effective transition to MAT.
BACKGROUND: Finding an effective, non-pharmacological approach to treat opioid withdrawal could remove some of the barriers associated with pharmacotherapy. The BRIDGE® is a noninvasive, percutaneous electrical nerve field stimulator developed to target pain. OBJECTIVES: This pilot study aimed to determine (1) the effects of the BRIDGE on withdrawal scores during the induction phase of opioid withdrawal therapy, (2) the percentage of subjects who successfully transitioned to medication assisted therapy (MAT). METHODS: Adult patients treated with the BRIDGE during medically supervised withdrawal were included in this open label, uncontrolled, and retrospective study. The clinical opioid withdrawal scale (COWS) scores were prospectively recorded at different intervals (20, 30, and 60 min) and analyzed retrospectively. A subset of patients had scores recorded 5-days post-BRIDGE. Those who returned to the clinic and received their first dose of maintenance medication were considered to be successfully transitioned. RESULTS: In this cohort (n=73), 65% were male. The mean COWS score prior to BRIDGE placement was 20.1 (±6.1). Twenty minutes after BRIDGE placement, the mean score was reduced to 7.5 (±5.9) (62.7% reduction, p<0.001). The scores further decreased after 30 minutes 4.0 (±4.4) and 60 minutes 3.1 (±3.4) (84.6% reduction, p<0.001). No rescue medications were administered during this period. The mean withdrawal score on day 5 was 0.6 (97.1% reduction, p<0.001) (n=33). Overall, 64/73 patients (88.8%) successfully transitioned to MAT. CONCLUSIONS: Neurostimulation with the BRIDGE is associated with a reduction in opioid withdrawal scores. This effect persisted during the induction period and allowed for effective transition to MAT.
Authors: James J Mahoney; Colleen A Hanlon; Patrick J Marshalek; Ali R Rezai; Lothar Krinke Journal: J Neurol Sci Date: 2020-09-20 Impact factor: 3.181
Authors: Eugenijus Kaniusas; Stefan Kampusch; Marc Tittgemeyer; Fivos Panetsos; Raquel Fernandez Gines; Michele Papa; Attila Kiss; Bruno Podesser; Antonino Mario Cassara; Emmeric Tanghe; Amine Mohammed Samoudi; Thomas Tarnaud; Wout Joseph; Vaidotas Marozas; Arunas Lukosevicius; Niko Ištuk; Antonio Šarolić; Sarah Lechner; Wlodzimierz Klonowski; Giedrius Varoneckas; Jozsef Constantin Széles Journal: Front Neurosci Date: 2019-08-09 Impact factor: 4.677
Authors: Brian M Ilfeld; John J Finneran; Engy T Said; Krishna R Cidambi; Scott T Ball Journal: J Trauma Acute Care Surg Date: 2022-05-21 Impact factor: 3.697
Authors: Carlos F Tirado; Stephanie N Washburn; Alejandro Covalin; Caroline Hedenberg; Heather Vanderpool; Caroline Benner; Daniel P Powell; Melanie A McWade; Navid Khodaparast Journal: Bioelectron Med Date: 2022-08-18
Authors: Brian M Ilfeld; John J Finneran Iv; David Dalstrom; Anne M Wallace; Baharin Abdullah; Engy T Said Journal: Reg Anesth Pain Med Date: 2022-06-17 Impact factor: 5.564